Related Experiment Video
Updated: May 11, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Synthesis and evaluation of a new phosphorylated ribavirin prodrug
Steven D Dong1, Chin-Chung Lin, Mel Schroeder
1Epiphany Biosciences, Inc., San Francisco, CA 94111, USA. steved@epiphanybio.com
Abstract:
Ribavirin is an important broad-spectrum antiviral drug. However, its utilization can be limited by its potential to cause hemolytic anemia as well as its variability in dosing levels and efficacy outcomes. To overcome these issues, we report on a new alkoxyalkylphosphodiester prodrug of ribavirin (2) that is designed to release the active ribavirin-monophosphate species selectively in nucleated cells while limiting its exposure in anucleated red blood cells (RBCs). Prodrug 2 displays improved in vitro antiviral activity against the hepatitis C virus replicon and influenza virus. Unlike ribavirin, prodrug 2 does not significantly decrease ATP levels in RBCs. Prodrug 2 demonstrates decreased uptake in RBCs but increased uptake in HepG2 hepatocytes when compared to ribavirin. In vivo, prodrug 2 is orally bioavailable and well-tolerated in rats in which it is processed to ribavirin and accumulates in the liver. These results indicate that prodrug 2 has the potential for safer, lower, less frequent, and less variable administration than ribavirin.
More Related Videos
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Prodrugs
Prodrugs help overcome...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Subviral Agents

